Therefore, the considerable interest in targeting eosinophil populations resulted in the implementation of the following treatments: (1) anti-common beta (β) chain therapy, which targets IL-5, IL-3, and GM-CSF-associated growth factors; (2) anti-chemotaxis therapy, which inhibits the activity of migration via targeting chemokines and their receptors; and (3) anti-cytokine specific therapy, which uses monoclonal antibodies against IL-4, IL-5, and IL-13, which influence eosinophil differentiation and activation in eosinophil-associated diseases such as asthma [128]. This evidence concerns the gene CSF2 and asthma.